5 results about "Genomic Stability" patented technology

The application belongs to the technical field of genetic engineering and cell modification, and discloses a genetic engineering construction method and application of an anti-aging human mesenchymal stem cell. Based on eliminating R-loop formed in the process of cell aging from the source, relieving the adverse effects of genome instability caused by R-loop, the application develops RNH1 overexpression virus transfection MSC aiming at eliminating cell R-loop. The RNH1 overexpression MSC provided by the application exhibits significant anti-aging activity, has strong environmental adaptability and excellent safety characteristics, can effectively resist harsh in-vivo inflammation and aging microenvironment, and avoid the tumorigenic risk after cell transplantation, and the MSCs with stable anti-aging ability can be applied to significantly improve the curative effect of MSCs infusion in-vivo disease treatment.

The invention discloses a macaque skin squamous carcinoma cell line MCSCC14397 and application of the macaque skin squamous carcinoma cell line MCSCC14397. The macaque skin squamous carcinoma cell line is named as macaque skin squamous carcinoma cell line MCSCC14397, and the preservation number of the macaque skin squamous carcinoma cell line is CCTCC (China Center For Type Culture Collection) NO: C2025156. The cell line disclosed by the invention has similar protein expression with primary tumor tissues, has chromosome abnormal karyotype, in-vitro tumor formation capability and stable proliferation characteristics, and simultaneously shows remarkable genome instability (such as high-frequency Cgt, T mutation and structural variation) and inflammation signal activation. The MYO10 gene expression in the cell line is up-regulated and drives DNA damage reaction and inflammatory factor expression, and unique advantages are provided for application of the cell line in skin squamous cell carcinoma mechanism research, drug screening and drug efficacy evaluation. The cell line disclosed by the invention can be used as an effective cell model, can be used for establishing a xenotransplantation animal model, and can provide a research basis for deeply researching the occurrence, development, metastasis mechanism and drug resistance mechanism of human skin squamous cell carcinoma as well as innovative drug development and screening.

The invention provides an organic-solvent-free cell cryopreservation and separation integrated method, and belongs to the technical field of crossing of nano materials and biomedicine. According to the method, a non-permeable cryoprotectant is efficiently delivered into target cells through a targeting delivery system mediated by a cell targeting recognition ligand, and organic-solvent-free efficient cryopreservation and high-purity separation of the target cells are synchronously realized by utilizing the survival difference between the target cells and non-target cells in the freezing and thawing cycle process. According to the method, a cryopreservation effect equivalent to that of 10% dimethyl sulfoxide (DMSO) is realized, and the stability of a target cell genome is remarkably improved due to avoidance of the toxicity of the DMSO; meanwhile, the separation purity higher than 95% can be achieved without depending on mechanical separation, and multiple cell damage caused by shear stress in the conventional separation process, ice crystal damage during cryopreservation and cryoprotectant toxicity is effectively avoided.

The present application relates to the technical field of genetic engineering and cell biology, and particularly relates to a universal human induced pluripotent stem cell, PD-L1 The promoter is inserted into a short enhancer sequence, the short enhancer sequence has the characteristics of enhancing the expression of PD-L1 when being differentiated into dopaminergic neural precursor cells or dopaminergic neuron cells, and the short enhancer sequence is selected from any one of TSE012, TSE026, TSE053, TSE075 and TSE089. The present application also relates to a ready-to-use mDAP / mDA cell and application, has cell type-specific immune escape, only when the cell is differentiated into mDAP / mDA, the expression of immune rejection genes PD-L1 and CTLA4 is started, has little influence on genomic stability, and in-situ activation of gene expression is realized.